Financial insights of CCEL

MyFinsight

For the quarter ending 2026-02-28, CCEL made $7,683,117 in revenue. $47,108 in net income. Net profit margin of 0.61%.

Income Statement	2026-02-28	2025-11-30	2025-08-31	2025-05-31
Revenue	7,683,117	7,934,908.5*	7,825,432	7,928,843
Cost of sales	1,656,488	1,889,711*	1,801,419	1,856,539
Selling, general and administrative expenses	5,011,847	9,288,809.5*	3,876,159	4,257,857
Impairment of investment-Tianhe Stem Cell Biotechnologies Inc	-	0*	0	0
Impairment of public inventory	-	1,089,708.5*	-	-
Research, development and related engineering	65,761	86,259*	61,625	131,711
Depreciation and amortization	183,887	187,781.5*	185,693	190,102
Total costs and expenses	6,917,983	12,542,269.5*	5,924,896	6,436,209
Operating income	765,134	-4,607,361*	1,900,536	1,492,634
Gaines on marketable securities	-240,458	53,560*	-193,886	-379,332
Gain on interest rate swap	-	0*	0	0
Other income	8,342	7,238*	17,565	12,927
Interest expense	462,709	432,238.5*	538,219	551,126
Total other (expense) income	-694,825	-371,440.5*	-714,540	-917,531
Income before income tax expense	70,309	-4,978,801.5*	1,185,996	575,103
Income tax expense	23,201	-891,627*	436,588	219,318
Net income	47,108	-4,087,174.5	749,408	355,785

Basic EPS	0.01	-0.507	0.09	0.04
Diluted EPS	0.01	-0.51	0.09	0.04
Basic Average Shares	8,055,150	8,068,390	8,057,780	8,080,161
Diluted Average Shares	8,056,133	8,006,957	8,073,654	8,125,720